ArticleMicrobial cell factories2025
Harnessing magnetic cross-linked cell aggregates (CLCAs) for cost-effective preparation of Konjac mannan-oligosaccharide.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Konjac mannan oligosaccharides (KMOS) are currently popular in food additives for their health benefits. However, the simple and efficient preparation of KMOS is still a challenge. In this study, A novel gene encoding β-mannanase (CsMan134) from Cellvibrio sp. KY-GH-1 was displayed on the surface of E. coli cells. Subsequently, E.coli cells (3 g/L) expressing the mannanase CsMan134 were immobilized using 8% (w/v) polyvinyl alcohol, 3% (w/v) sodium alginate, and 3.5% (w/v) Fe₃O₄ to construct magnetic cross-linked cell aggregates (mag-CLCAs). The mannanase CsMan134 demonstrated the highest catalytic efficiency towards konjac mannan compared to other mannans. Compared to free enzyme, the mag-CLCAs exhibited enhanced enzymatic activity across a range of temperatures and pH levels. Furthermore, the mag-CLCAs showed improved thermal stability, retaining over 80% of its initial activity after heating at 50 °C for 180 min, whereas the free enzyme retained only 50% of its residual activity. Scanning electron microscopy (SEM) and vibrating sample magnetometry (VSM) analyses indicated that the mag-CLCAs also maintained good operational stability, retaining more than 75% of their initial activity over five cycles. The mag-CLCAs were effective in converting konjac mannan into a substantial amount of oligosaccharides with a degree of polymerization (DP) of 2-4. In conclusion, the mag-CLCAs represent a valuable, efficient, and cost-effective biocatalyst for the production of KMOS for industrial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.